Raymond James Financial Inc. Purchases Shares of 746,406 Hims & Hers Health, Inc. (NYSE:HIMS)

Raymond James Financial Inc. purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 746,406 shares of the company’s stock, valued at approximately $18,048,000. Raymond James Financial Inc. owned approximately 0.34% of Hims & Hers Health at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Crewe Advisors LLC bought a new stake in Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. US Bancorp DE lifted its holdings in Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after purchasing an additional 1,508 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in shares of Hims & Hers Health during the fourth quarter valued at approximately $48,000. 63.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HIMS has been the topic of several recent analyst reports. Citigroup reiterated a “sell” rating and set a $27.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Bank of America reiterated an “underperform” rating and issued a $21.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $34.68 on Tuesday. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The firm has a market capitalization of $7.70 billion, a P/E ratio of 78.82 and a beta of 1.37. The stock’s fifty day moving average is $38.64 and its two-hundred day moving average is $28.37.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In related news, CEO Andrew Dudum sold 36,460 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the sale, the chief executive officer now owns 27,918 shares in the company, valued at $756,298.62. The trade was a 56.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Melissa Baird sold 67,687 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $29.35, for a total value of $1,986,613.45. Following the completion of the sale, the chief operating officer now owns 706,872 shares of the company’s stock, valued at approximately $20,746,693.20. This represents a 8.74 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 890,592 shares of company stock worth $31,677,291. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.